AMPLER
1.11.2021 14:53:09 CET | Business Wire | Press release
Ampler has closed an equity round led by seasoned investors Taavet Hinrikus and Sten Tamkivi from Taavet+Sten and joined by top Estonian investors such as Metaplanet, Ambient Sound Investments and Ragnar Sass. The total size of the equity investment was 7.4 M € which puts the company valuation to 47 M €.
The fast-growing company will use the capital to continue building the future of personal transport by tackling the urban commuting problem. Ampler continues its expansion by doubling the head count and showrooms in 2022 as well as building a new carbon neutral factory by 2023. The global e-bike market is expected to reach $118.6 billion by 2030, according to Allied Market Research .
Taavet+Sten's vision is to promote the technology sector in Europe, including Estonia, with a decades-long view. Their investment firm invests the money and expertise of the owners themselves with the aim of supporting companies with future solutions over the long term. "As entrepreneurs and leaders, we have been building companies together since high school and have learned that the best way to create value for the world with technology is to be ingenious at solving some very complex problems. Ampler is moving in the right direction to ensure a cleaner planet for us," said Sten Tamkivi.
Ampler’s plans are to establish The Netherlands and Switzerland as the next core markets alongside Germany, by opening new showrooms and service centers. The next showroom will be opened in the vibrant Haarlemmerbuurt neighbourhood in Amsterdam. Ampler aims to become a role model for environmental sustainability for the cycling industry as expansion plans include opening a new carbon neutral factory, with the assembly capacity of at least 100 000 bikes a year. “All Ampler e-bikes are hand assembled in our own factory, as we believe that self-owned assembly will continue to be an important competitive advantage in order to offer the best urban commuting experience with user friendly, reliable and sustainably built light electric bikes,” comments Ardo Kaurit, CEO & co-founder of Ampler Bikes.
“I joined the Ampler round because they are boosting the most climate-friendly transportation mode - bicycles. And as an active user of Ampler e-bikes - I know that their products are truly the best in the world - both by the quality and service. I am sure the company has all it needs to become another unicorn from Estonia,” Ragnar Sass, co-founder of Estonian 5th unicorn Pipedrive and active angel investor in greentech.
“We are really proud to start this next chapter with investors and entrepreneurs who we look up to and believe that we can have a successful and long-lasting journey together which will be beneficial for all shareholders as well as our existing and future customers,” comments Ardo Kaurit.
About Ampler
Ampler Bikes is an Estonian direct to consumer brand that manufactures and sells light e-bikes. Founded in 2016 by a professional motocross racer, an engineer and a bicycle designer, Ampler launched their flagship e-bikes, the Ampler Curt, Stout and Stellar in 2018, and opened a showroom in Berlin in the same year. To date, Ampler has sold thousands of e-bikes across Europe, and has 130 people working between offices in Tallinn, Berlin and Cologne.
https://www.facebook.com/amplerbikes
https://www.instagram.com/amplerbikes/
https://www.youtube.com/amplerbikes
View source version on businesswire.com: https://www.businesswire.com/news/home/20211101005635/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom